Helicobacter pylori positive chronic gastritis
Conditions
Interventions
A Group:Bifidobacterium triple live bacteria enteric coated capsules 420mg Twice a day+Quadruple therapy
B Group:Bifidobacterium triple live bacteria enteric coated capsules 840mg Twice a day+Quadruple therapy
C Group:Quadruple therapy
Sponsors
The Fourth Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) HP positive chronic gastritis patients who meet the indications for HP eradication (2) All selected diagnoses must be obtained through gastroscopy examination (within 1 month) (3) Positive results in rapid urease test, urea breath test within 2 weeks before gastroscopy, or within 1 month after gastroscopy (4) Age range from 18 to 65 years old, regardless of gender (5) Has not received formal HP eradication treatment in the past (6) I haven't taken any probiotic preparations recently (7) Sign informed consent form
Exclusion criteria
Exclusion criteria: (1) Individuals who have used probiotics, antibiotics, bismuth supplements within 4 weeks prior to treatment, or who have used H2RA and PPI within 2 weeks prior to treatment; Long term use of non steroidal anti-inflammatory drugs in the past. (2) Pregnant or lactating women (3) The patient also has other serious diseases that affect the evaluation of this study, such as severe liver disease, heart disease, cerebrovascular disease, kidney disease, malignant tumors, and alcoholism (4) Individuals who are allergic to the drugs used in this study (5) Participated in other drug studies within the three months prior to using the investigational drug (6) Patients may not be able to express their complaints correctly, such as mental illness, severe neurosis, or inability to cooperate with this trial. (7) Patients with severe immunodeficiency who are prone to fungal infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 13 carbon breath test;Loss of appetite;Taste disorders;Early satiety;Nausea and vomiting;abdominal distension;abdominal pain;Acid reflux;Heartburn;diarrhea;constipation;fever;rash;Dizziness and headache;Compliance evaluation;Degree of symptom improvement; | — |
Countries
China
Contacts
Public ContactKang Qile
the Fourth Affiliated Hospital of Nanchang University
Outcome results
None listed